FDA draft guidance on compounding and repackaging

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2015年 / 1540卷 / 1期
关键词：
D O I：
10.1007/s40278-015-7850-y
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2 / 2
相关论文
共 50 条
  • [1] FDA draft guidance on compounding animal drugs from bulk drug substances: a commentary
    Adel H. Karara
    AAPS Open, 2 (1)
  • [2] FDA's draft guidance on pharmacogenomics
    Hellman, K
    Smith, D
    GENETIC ENGINEERING NEWS, 2005, 25 (04): : 18 - +
  • [3] FDA Draft Guidance on the Naming of Biosimilars
    Fernandez-Lopez, Sara
    BIODRUGS, 2015, 29 (05) : 323 - 325
  • [4] New FDA Draft Guidance on Immunogenicity
    Ashwin Parenky
    Heather Myler
    Lakshmi Amaravadi
    Karoline Bechtold-Peters
    Amy Rosenberg
    Susan Kirshner
    Valerie Quarmby
    The AAPS Journal, 2014, 16 : 499 - 503
  • [5] FDA Draft Guidance on the Naming of Biosimilars
    Sara Fernandez-Lopez
    BioDrugs, 2015, 29 : 323 - 325
  • [6] FDA stability draft guidance documents
    不详
    LARGE ANIMAL PRACTICE, 1998, 19 (06): : 12 - 12
  • [7] New FDA Draft Guidance on Immunogenicity
    Parenky, Ashwin
    Myler, Heather
    Amaravadi, Lakshmi
    Bechtold-Peters, Karoline
    Rosenberg, Amy
    Kirshner, Susan
    Quarmby, Valerie
    AAPS JOURNAL, 2014, 16 (03): : 499 - 503
  • [8] FDA issues nanotech draft guidance
    Nachay, Karen
    FOOD TECHNOLOGY, 2012, 66 (06) : 16 - 16
  • [9] Critical draft guidance issued for bulk compounding drugs
    Reactions Weekly, 2018, 1696 (1) : 1 - 1
  • [10] FDA isues draft crude heparin guidance
    Ritter, Amy
    Pharmaceutical Technology, 2012, 36 (03) : 24 - 27
12345